5-methoxy-2-methyl-2,3-dihydro-1H-inden-1-one | 60848-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-methoxy-2-methyl-2,3-dihydro-1H-inden-1-one
• 英文别名: 5-Methoxy-2-methylindan-1-one；5-methoxy-2-methyl-2,3-dihydroinden-1-one
• CAS: 60848-62-6
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: MVAUIZRRRJGZHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methoxy-2-methyl-2,3-dihydro-1H-inden-1-one 在 sodium hydride 、 一水合肼 作用下， 以 溶剂黄146 为溶剂， 反应 24.67h， 生成 4,4a-dihydro-7-methoxy-4a-methyl-5H-indeno<1,2-c>pyridazin-3(2H)-one
  参考文献：
  名称：

  Inotropic, vasodilator and low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) inhibitory activities of 4a-methyl-4,4a-dihydro-5H-indeno[1,2-c]pyridazin-3(2H)-ones and 4a-methyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-ones

  摘要：

  Novel 7-substituted-4,4a-dihydro-4a-methyl-5H-indenol[1,2-c]pyridazin-3[2H]-ones and 8-substituted-4a-methylbenzo[h]cinnolin-3[2H]-ones have been synthesized and their PDE III inhibitory, inotropic and vasodilator potencies compared with those of their normethyl analogues and their bicyclic 4,5-dihydro-6-phenylpyridazinone analogues. The structure-activity relationships of the tricyclic pyridazinones differ from those of bicyclic pyridazinones mainly in respect of the effect of introducing the methyl group into the pyridazinone ring. Whilst in the 4,5-dihydro-6-phenylpyridazin-3(2H)-ones, introduction of a 5-methyl group has been widely reported to lead to compounds of significantly greater potency, the novel tricyclic 4a-methylpyridazinones showed similar levels of inotropic, vasodilator and PDE III inhibitory potency to their normethyl analogues. Possible reasons for this difference in behaviour are discussed.

  DOI：

  10.1016/0223-5234(90)90196-a
• 作为产物：
  描述：

  (Z)-3-(4-甲氧基苯基)-2-甲基-丙-2-烯酸 在 5%-palladium/activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 50.0~70.0 ℃ 、275.8 kPa 条件下， 反应 0.5h， 生成 5-methoxy-2-methyl-2,3-dihydro-1H-inden-1-one
  参考文献：
  名称：

  INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF

  摘要：

  揭示了化合物，例如，具有公式I的化合物，其中R、R0、R1-R8、n、X、Y、Y′和E如本文所述，包含这些化合物的药物组合物，以及治疗或预防疾病或病症的方法，例如癌症。

  公开号：

  US20160168113A1

文献信息

• Estrogen receptor modulators
  申请人：——

  公开号：US20030027840A1

  公开（公告）日：2003-02-06

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

  本发明涉及化合物及其衍生物、它们的合成方法以及它们作为雌激素受体调节剂的应用。本发明的化合物是雌激素受体的配体，因此可用于治疗或预防与雌激素功能相关的多种疾病，包括：骨丢失、骨折、骨质疏松症、软骨退化、子宫内膜异位症、子宫纤维瘤病、热潮红、LDL胆固醇水平升高、心血管疾病、认知功能损害、脑部退行性疾病、再狭窄、男性乳房发育、血管平滑肌细胞增殖、肥胖、失禁以及癌症，尤其是乳腺癌、子宫癌和前列腺癌。
• Total Synthesis and Stereochemical Assignment of Delavatine A: Rh-Catalyzed Asymmetric Hydrogenation of Indene-Type Tetrasubstituted Olefins and Kinetic Resolution through Pd-Catalyzed Triflamide-Directed C–H Olefination
  作者：Zhongyin Zhang、Jinxin Wang、Jian Li、Fan Yang、Guodu Liu、Wenjun Tang、Weiwei He、Jian-Jun Fu、Yun-Heng Shen、Ang Li、Wei-Dong Zhang

  DOI：10.1021/jacs.7b01718

  日期：2017.4.19

  Delavatine A (1) is a structurally unusual isoquinoline alkaloid isolated from Incarvillea delavayi. The first and gram-scale total synthesis of 1 was accomplished in 13 steps (the longest linear sequence) from commercially available starting materials. We exploited an isoquinoline construction strategy and developed two reactions, namely Rh-catalyzed asymmetric hydrogenation of indene-type tetrasubstituted

  Delavatine A (1) 是一种结构不寻常的异喹啉生物碱，从 Incarvillea delavayi 中分离出来。第一次和克级规模的 1 全合成是在 13 步（最长的线性序列）中从市售起始材料中完成的。我们利用异喹啉构建策略并开发了两个反应，即Rh 催化的茚型四取代烯烃的不对称氢化和通过 Pd 催化的三氟甲磺酸酰胺导向的 CH 烯化对 β-烷基苯乙胺衍生物进行动力学拆分。第一个反应的底物范围包括未官能化的烯烃和含有极性官能团的烯烃，如磺胺类。动力学分辨率提供了一系列对映体富集的茚满和四氢萘基三氟甲酰胺，包括那些带有四元手性中心的三氟甲酰胺。许多底物的选择性因子超过 100。这些反应使两种不同但相关的方法能够以优异的对映纯度获得关键中间体 28。在合成中，三氟甲磺酸胺不仅是一个有效的 CH 键活化导向基团，而且还是一个多功能的官能团，可用于进一步的研究。Delavatine A 的
• Acid/Base-Co-catalyzed Formal Baeyer–Villiger Oxidation Reaction of Ketones: Using Molecular Oxygen as the Oxidant
  作者：Chun-Hua Liu、Zhuo Wang、Li-Yun Xiao、Mukadas、Dong-Sheng Zhu、Yu-Long Zhao

  DOI：10.1021/acs.orglett.8b02006

  日期：2018.8.17

  A novel acid/base-co-catalyzed formal Baeyer–Villiger oxidation of various ketones using O2 as the sole oxidant under metal-free conditions has been developed for the first time. The reaction tolerates a wide range of ketones and anilines and provides a simple and efficient method for the construction of various amides and isoquinolin-1-ones from the reactions of ketones with anilines in a single step

  首次开发了在无金属条件下使用O 2作为唯一氧化剂的新型酸/碱共催化的各种酮的正式拜耳-维利格氧化方法。该反应可耐受各种酮和苯胺，并提供了一种简单有效的方法，可通过一步在酮与苯胺的反应中构建各种酰胺和异喹啉-1-酮。
• Compounds useful in therapy
  申请人：Bryans Stephen Justin

  公开号：US20050154024A1

  公开（公告）日：2005-07-14

  Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: X represents —[CH 2 ] a —R or —[CH 2 ] a —O—[CH 2 ] b —R; a represents a number selected from 0 to 6; b represents a number selected from 0 to 6; R represents H, CF 3 or Het; Het represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; Y represents one or more substituents independently selected from —[O] c —[CH 2 ] d —R 1 , which may be the same or different at each occurrence; c at each occurrence independently represents a number selected from 0 or 1; d at each occurrence independently represents a number selected from 0 to 6; R 1 at each occurrence independently represents H, halo, CF 3 , CN or Het 1 ; Het 1 at each occurrence independently represents a 5- or 6-membered unsaturated heterocyclic ring; V represents a direct link or —O—; Ring A represents an optionally substituted 5- to 7-membered saturated heterocyclic ring, or a phenylene group; Q represents a direct link or —N(R 2 )—; R 2 represents hydrogen or C 1-6 alkyl; Z represents —[O] e —[CH 2 ] f —R 3 , a phenyl ring (optionally fused to a benzene ring or Het 2 , and the group as a whole being optionally substituted), or Het 3 (optionally fused to an benzene ring or Het 4 , and the group as a whole being optionally substituted); R 3 represents C 1-6 alkyl (optionally substituted), C 3-6 cycloalkyl, C 3-6 cycloalkenyl, phenyl (optionally substituted), Het 5 or NR 4 R 5 ; e represents a number selected from 0 or 1; f represents a number selected from 0 to 6; Het 2 and Het 5 independently represent optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic rings; Het 3 represents an optionally substituted 4 to 6-membered saturated, partially saturated or aromatic heterocyclic ring; Het 4 represents an optionally substituted 6-membered aromatic heterocyclic ring; R 4 and R 5 independently represent optionally substituted C 1-6 alkyl, C 1-6 alkyloxy, C 3-8 cycloalkyl (optionally fused to C 3-8 cycloalkyl), Het 6 , or hydrogen; Het 6 represents an optionally substituted 5- or 6-membered saturated, partially saturated or aromatic heterocyclic ring; are useful for treating a disorder for which a V1 a antagonist is indicated.

  式(I)的化合物，或其药学上可接受的衍生物，其中： X代表—[CH 2 ] a —R或—[CH 2 ] a —O—[CH 2 ] b —R；a代表从0到6中选择的数字；b代表从0到6中选择的数字； R代表H，CF 3 或Het；Het代表一个可选择取代的5-或6-成员饱和、部分饱和或芳香杂环环； Y代表一个或多个取代基，独立地选择自—[O] c —[CH 2 ] d —R 1 ，每次出现时可能相同也可能不同；c在每次出现时独立地代表从0或1中选择的数字；d在每次出现时独立地代表从0到6中选择的数字； R 1 在每次出现时独立地代表H，卤素，CF 3 ，CN或Het 1 ； Het 1 在每次出现时独立地代表一个5-或6-成员不饱和杂环环；V代表一个直链或—O—；环A代表一个可选择取代的5-到7-成员饱和杂环环，或一个苯基团； Q代表一个直链或—N(R 2 )—； R 2 代表氢或C 1-6 烷基； Z代表—[O] e —[CH 2 ] f —R 3 ，一个苯环（可选择与苯环或Het 2 融合，并且整体作为可选择取代的团），或Het 3 （可选择与苯环或Het 4 融合，并且整体作为可选择取代的团）； R 3 代表C 1-6 烷基（可选择取代），C 3-6 环烷基，C 3-6 环烯基，苯基（可选择取代），Het 5 或NR 4 R 5 ；e代表从0或1中选择的数字；f代表从0到6中选择的数字； Het 2 和Het 5 独立地代表可选择取代的5-或6-成员饱和、部分饱和或芳香杂环环； Het 3 代表一个可选择取代的4到6-成员饱和、部分饱和或芳香杂环环； Het 4 代表一个可选择取代的6-成员芳香杂环环； R 4 和R 5 独立地代表可选择取代的C 1-6 烷基，C 1-6 烷氧基，C 3-8 环烷基（可与C 3-8 环烷基融合），Het 6 ，或氢； Het 6 代表一个可选择取代的5-或6-成员饱和、部分饱和或芳香杂环环；适用于治疗需要V1 a 拮抗剂的紊乱。
• Indanylidene compounds
  申请人：Roche Vitamins Inc.

  公开号：US06416746B1

  公开（公告）日：2002-07-09

  The invention relates to novel indanylidene compounds which are effective in absorbing ultra violet radiation and to light screening compositions including the indanylidene compounds of the general formula I wherein X is O or NH; R1 is a C1-C20 alkyl, C2-C20 alkyl in which at least one methylene group is replaced by oxygen, C3-C20 alkenyl, C3-C20 alkynyl or a group YS; R2 is a C1-C20 alkyl, C2-C20 alkyl in which at least one methylene group is replaced by oxygen, C3-C20 alkenyl, C3-C20 alkynyl or a group YS; or R1 and R2 may combine on adjacent C-atoms to form a dioxomethylene ring; R3 is a C1-C20 alkyl, C2-C20 alkyl in which at least one methylene group is replaced by oxygen, C3-C20 alkenyl, C3-C20 alkynyl or a group YS; R4, R5, R6 are each independently H or C1-C20 alkyl; n is 0, 1 or 2; Y is a linker group; S is a silane-, an oligosiloxane- or a polysiloxane-moiety; with the proviso that at least one of the R1, R2or R3 residues is YS. Methods for protecting skin from UV damage using a light screening agent containing one of the indanylidene compounds of the present invention are also provided.

  该发明涉及一种新型吲哚亚甲基化合物，其在吸收紫外辐射方面具有有效性，并且涉及包括具有一般式I的吲哚亚甲基化合物的光屏蔽组合物，其中X为O或NH；R1为C1-C20烷基，C2-C20烷基，其中至少一个亚甲基团被氧替代，C3-C20烯基，C3-C20炔基或YS基团；R2为C1-C20烷基，C2-C20烷基，其中至少一个亚甲基团被氧替代，C3-C20烯基，C3-C20炔基或YS基团；或者R1和R2可以在相邻的碳原子上结合形成二氧亚甲基环；R3为C1-C20烷基，C2-C20烷基，其中至少一个亚甲基团被氧替代，C3-C20烯基，C3-C20炔基或YS基团；R4、R5、R6分别独立地为H或C1-C20烷基；n为0、1或2；Y为连接基团；S为硅烷基、寡硅氧烷基或聚硅氧烷基；但至少其中一个R1、R2或R3残基为YS。还提供了使用含有本发明吲哚亚甲基化合物之一的光屏蔽剂保护皮肤免受紫外线损伤的方法。